Abstract
This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.
| Translated title of the contribution | Not Available |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 185 |
| Issue number | 32 |
| ISSN | 0041-5782 |
| Publication status | Published - 7 Aug 2023 |